Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
22.60
+0.11 (0.49%)
Jan 30, 2025, 4:00 PM EST - Market closed
Rigel Pharmaceuticals Revenue
Rigel Pharmaceuticals had revenue of $55.31M in the quarter ending September 30, 2024, with 96.58% growth. This brings the company's revenue in the last twelve months to $157.37M, up 21.65% year-over-year. In the year 2023, Rigel Pharmaceuticals had annual revenue of $115.78M with 0.03% growth.
Revenue (ttm)
$157.37M
Revenue Growth
+21.65%
P/S Ratio
2.52
Revenue / Employee
$1,070,571
Employees
147
Market Cap
398.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 115.78M | 40.00K | 0.03% |
| Dec 31, 2022 | 115.74M | -22.99M | -16.57% |
| Dec 31, 2021 | 138.74M | 30.12M | 27.72% |
| Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
| Dec 31, 2019 | 59.29M | 14.78M | 33.20% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.95B |
RIGL News
- 8 days ago - Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - PRNewsWire
- 17 days ago - Rigel Provides Business Update and 2025 Outlook - PRNewsWire
- 21 days ago - Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS - PRNewsWire
- 22 days ago - Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 27 days ago - Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents - Seeking Alpha
- 7 weeks ago - Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition - PRNewsWire
- 2 months ago - Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS - PRNewsWire